ReviewPituitary2026
Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.
Review in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextRadiotherapy is used as second- or third-line treatment after transsphenoidal surgery for both functioning and nonfunctioning pituitary adenomas. Improved precision delivery may reduce side effects, but use overall has declined, partly due to improved surgical technique and advances in medical therapy, partly reflecting a shift from fractionated radiotherapy to stereotactic radiosurgery in appropriately selected patients, and also due to lack of clear, evidence-based guidelines. Questions remain regarding radiotherapy indications, optimal timing, choice of technique, and follow-up for efficacy and side effects. The aim of this Delphi panel was to establish expert consensus in these areas.
designThe Pituitary Society Steering Committee conducted a modified two-round Delphi panel with 29 international experts from five continents, including neuroendocrinologists, neurosurgeons and radiation oncologists.
resultsAmong the 26 initial statements, 22 (84.6%) reached agreement after Round 1. Four statements were reconsidered in Round 2, together with an additional question, after which 24 of 27 (88.9%) reached consensus. Panelists agreed that radiotherapy indication and timing should be assessed by expert multidisciplinary tumor boards, including a radiation oncologist, with the technique determined according to patient and adenoma characteristics. They emphasized controlling hormonal secretion while waiting for maximal radiotherapy efficacy in functioning adenomas. Long term follow-up > 10 years is required to assess for delayed efficacy, recurrence and side effects, although panelists agreed on the relatively low medium-term risk with modern techniques.
conclusionModified Delphi panel provides practical guidance regarding indications, timing, choice of technique and long-term follow-up of radiotherapy in pituitary adenomas. Modern techniques appear as effective and potentially safer vs. previous ones. Further long-term comparative data are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.